Key facts
- Aveta Biomics’s last known valuation is $50.6M (Feb 2022).
- It has raised $9.7M across 3 recorded rounds; the latest was Seed Round ($4.5M) in May 2024.
- Aveta Biomics has filed 3 Form Ds with the SEC since 2018, most recently Mar 2025 ($4.5M sold to 36 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Aveta Biomics
Funding rounds
3 roundsAbout Aveta Biomics
Developer of nature-inspired drugs designed to provide a durable response to cancer patients. The company's drugs use botanical extracts and are based on the judicious combination of botanical molecules that can simultaneously modulate a network of multiple targets that are likely to be effective, enabling medical professionals to have access to effective and safe drugs to both treat and prevent cancers.
- Sector
- Healthcare
- HQ
- Bedford, MA, United States
- Founded
- 2014
- Website
- avetabiomics.com/
- Ownership
- Privately Held (backing)
Aveta Biomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aveta Biomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aveta Biomics in its N-PORT filings yet. We sweep new filings monthly.